A composite probiotic for preventing and treating colitis and its application
Through the combination of the Pediococcus acidilactici PA53 strain and Lactobacillus helveticus LH76 strain, the problem of limited effect of existing probiotics in the treatment of colitis is solved, and significant symptom relief and intestinal bacterial improvement are achieved. It significantly improves the prevention and treatment effect of colitis.
Patent Information
- Application Number
- CN202410931590.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-07-12
AI Technical Summary
The existing application of probiotics in colitis treatment is still in its infancy, and effective compound bacterial strategies are lacking to alleviate the symptoms of colitis and improve intestinal flora imbalance.
The combination of the Pediococcus acidilactici PA53 strain and Lactobacillus helveticus LH76 strain was adopted. Through mutual cooperation and synergy, the effect of preventing and treating colitis was significantly improved, including alleviating weight loss, reducing disease activity index, and restoring colon length. , improve inflammatory factor disorders and oxidative stress responses, and increase short-chain fatty acid content.
This compound method significantly improves the effect of preventing and treating colitis when the amount of bacteria is used is consistent, and it is more effective than the intervention of a single bacterial species. It is also highly safe and does not easily develop resistance.
Smart Images

Figure CN118460440B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms and relates to a composite probiotic for preventing and treating colitis and application thereof. Background Art
[0002] Colitis, especially ulcerative colitis, is a chronic nonspecific inflammatory disease. Its etiology penetrates deep into the colon mucosa and its underlying layers. Factors such as immune abnormalities, genetic predispositions, and intestinal flora imbalance play a key role in its pathogenesis.
[0003] The treatment of colitis mainly focuses on maintaining the condition to reduce the patient's risk of colorectal cancer. Probiotics, as a class of active microorganisms that can play a positive role in the human body, have shown great potential in the treatment of colitis. Probiotics play an important role in the treatment of colitis through a series of complex mechanisms. First, they can competitively inhibit the colonization of pathogenic bacteria in the intestinal epithelium and effectively reduce the damage of these pathogens to the intestinal mucosa. Secondly, probiotics can significantly improve the intestinal microecological environment, increase the number of beneficial bacteria, and reduce the proportion of harmful bacteria, thereby effectively alleviating the problem of intestinal flora disorder in patients with colitis. In addition, probiotics can also stimulate the intestinal mucosal immune system, improve local immune levels, and enhance the body's defense against pathogenic bacteria. Finally, probiotics can also promote the proliferation and repair of intestinal mucosal cells, thereby alleviating the symptoms of intestinal inflammation in patients with colitis.
[0004] The application of probiotics in the prevention and treatment of colitis is still in its early stages, and there are still few strategies. Therefore, developing more probiotics to improve colitis can provide new ideas and methods for the treatment of colitis. Summary of the invention
[0005] In view of the deficiencies of the prior art, the object of the present invention is to provide a composite probiotic for preventing and treating colitis and its application.
[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0007] In a first aspect, the present invention provides a composite probiotic for preventing and treating colitis, wherein the composite probiotic for preventing and treating colitis is composed of Pediococcus acidilactici with a preservation number of CGMCC No.18798. Pediococcus acidilactici PA53 strain and Lactobacillus helveticus with a deposit number of CGMCC No.18796 Lactobacillus helveticus LH76 strain composition.
[0008] The present invention creatively develops a new probiotic compounding method and a new strategy for preventing and treating colitis, namely, Pediococcus acidilactici Pediococcus acidilactici PA53 strain and Lactobacillus helveticus Lactobacillus helveticusThe LH76 strain was used in combination, and it was found that the two strains can cooperate with each other, promote each other, and synergize in the prevention and treatment of colitis, specifically: (1) Alleviate the weight loss caused by colitis, reduce the disease activity index, and restore the length of the colon; (2) Improve the inflammatory factor imbalance and oxidative stress response caused by colitis; (3) Increase the content of short-chain fatty acids in the intestine of colitis mice. When the amount of bacteria used is the same, the combination of the two bacteria has a significantly improved effect on the prevention and treatment of colitis compared with the intervention method without any one of the bacteria. At the same time, both bacteria are probiotics, the product is highly safe, and it is not easy to develop resistance.
[0009] Preferably, the ratio of the viable cell count of the PA53 strain to that of the LH76 strain is 1:5-5:1, for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, etc. Other specific point values within the above numerical range can be selected and will not be described here one by one.
[0010] In a second aspect, the present invention provides a probiotic for preventing and treating colitis, wherein the strain in the probiotic is the composite probiotic described in the first aspect.
[0011] Preferably, the viable bacterial contents of the PA53 strain and the LH76 strain in the probiotics are not less than 1×10 9 CFU / g or 1×10 9 CFU / mL, for example 1×10 9 CFU / g (CFU / mL), 1×10 10 CFU / g (CFU / mL), 5×10 10 CFU / g (CFU / mL), 1×10 11 CFU / g (CFU / mL), 3×10 11 CFU / g (CFU / mL), 5×10 11 CFU / g (CFU / mL), 1×10 12 CFU / g (CFU / mL), 1×10 13 CFU / g (CFU / mL), etc. Other specific point values within this numerical range can be selected and will not be described here one by one.
[0012] Preferably, the dosage form of the probiotics includes solutions, lyophilized powders, capsules, tablets or granules. The dosage form of the probiotics involved in the present invention is not limited, including the most commonly used solutions, lyophilized powders, or further prepared capsules, tablets or granules.
[0013] Preferably, the probiotic is in the form of a solution, which is prepared by the following method:
[0014] The PA53 strain and the LH76 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively and resuspended with a solvent to obtain a PA53 bacterial suspension and a LH76 bacterial suspension; the PA53 bacterial suspension and the LH76 bacterial suspension are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent.
[0015] Preferably, the probiotic is in the form of a freeze-dried powder, which is prepared by the following method:
[0016] The PA53 strain and the LH76 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively, mixed with a protective agent and freeze-dried to obtain PA53 bacterial powder and LH76 bacterial powder; the PA53 bacterial powder and the LH76 bacterial powder are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent.
[0017] In a third aspect, the present invention provides use of the composite probiotic described in the first aspect or the probiotic agent described in the second aspect in the preparation of a medicament for preventing, improving or treating colitis.
[0018] Preferably, the medicine further contains excipients.
[0019] Preferably, the auxiliary materials include any one or a combination of at least two of fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, colorants, pH regulators, antioxidants, antibacterial agents or buffers.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] The present invention creatively develops a new probiotic compounding method and a new strategy for preventing and treating colitis, namely, Pediococcus acidilactici Pediococcus acidilactici PA53 strain and Lactobacillus helveticus Lactobacillus helveticus The LH76 strain was used in combination, and it was found that the two strains can cooperate with each other, promote each other, and synergize in the prevention and treatment of colitis, specifically: (1) Alleviate the weight loss caused by colitis, reduce the disease activity index, and restore the length of the colon; (2) Improve the inflammatory factor imbalance and oxidative stress response caused by colitis; (3) Increase the content of short-chain fatty acids in the intestine of colitis mice. When the amount of bacteria used is the same, the combination of the two bacteria has a significantly improved effect on the prevention and treatment of colitis compared with the intervention method without any one of the bacteria. At the same time, both bacteria are probiotics, the product is highly safe, and it is not easy to develop resistance.
[0022] The PA53 strain involved in the present invention is classified and named as Pediococcus acidilactici Pediococcus acidilacticiThe depository is the General Microbiology Center of China Microbiological Culture Collection Administration. The deposit date is November 4, 2019. The deposit number is CGMCC No.18798. The address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing.
[0023] The LH76 strain involved in the present invention is classified and named as Lactobacillus helveticus Lactobacillus helveticus The depository is the General Microbiology Center of China Microbiological Culture Collection Administration. The deposit date is November 4, 2019. The deposit number is CGMCC No.18796. The address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 This is the result diagram of the weight changes of mice in each group during the modeling period;
[0025] Figure 2 This is a statistical graph of the colon length of each group of mice after the end of the experiment;
[0026] Figure 3 is the statistical result diagram of interleukin-6 levels in colon tissues of mice in each group;
[0027] Figure 4 This is a statistical result diagram of interleukin-10 levels in colon tissues of mice in each group;
[0028] Figure 5 This is a statistical result diagram of the interleukin-1β level in the colon tissue of each group of mice;
[0029] Figure 6 is the statistical result graph of tumor necrosis factor-α level in colon tissue of each group of mice;
[0030] Figure 7 is the statistical result diagram of myeloperoxidase activity in colon tissue of each group of mice;
[0031] Figure 8 is the statistical result diagram of superoxide dismutase activity in colon tissue of each group of mice;
[0032] Fig. 9 This is a statistical graph of the malondialdehyde content in the colon tissue of each group of mice. DETAILED DESCRIPTION
[0033] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0034] The culture medium formula involved in the following examples is as follows:
[0035] MRS medium: peptone 10g / L, beef extract 10g / L, glucose 20g / L, sodium acetate 2g / L, yeast powder 5g / L, diammonium hydrogen citrate 2g / L, K2PO4·3H2O 2.6g / L, MgSO4·7H2O 0.1g / L, MnSO4 0.05g / L, Tween 801mL / L, cysteine hydrochloride 0.5g / L.
[0036] The PA53 strain involved in the following examples is classified and named as Pediococcus acidilactici Pediococcus acidilactici The deposit date is November 4, 2019, and the deposit number is CGMCC No.18798.
[0037] The LH76 strain involved in the following examples is classified and named Lactobacillus helveticus Lactobacillus helveticus The deposit date is November 4, 2019, and the deposit number is CGMCC No.18796.
[0038] The following method for preparing a bacterial suspension involves: inoculating the desired strain into a liquid culture medium, culturing at 37°C for 24 hours for activation, and continuously activating twice to obtain an activated solution; inoculating the activated solution into a liquid culture medium at an inoculum rate of 5% (v / v), culturing at 37°C for 24 hours to obtain a bacterial solution; centrifuging the bacterial solution at 4°C and 5000 rpm for 10 minutes, filtering to obtain bacterial bodies, and resuspending the bacterial bodies in a PBS solution to obtain the product.
[0039] The experimental results were statistically analyzed using ggplot2 in R language. Compared with the control group, ### represents p<0.001, ## represents p<0.01, and # represents p<0.05; compared with the model group, *** represents p<0.001, ** represents p<0.01, * represents p<0.05, and NS represents no significant difference. Example
[0040] This example explores the ability of compound probiotics to improve symptoms in a colitis mouse model:
[0041] (1) Experimental animals: Healthy male C57BL / 6 mice, 7 weeks old (n=64), were housed in a controlled environment with room temperature maintained at 22-24°C, humidity at 50-60%, and a 12-h light / dark cycle. They were allowed to eat and drink freely.
[0042] (2) Animal grouping: After one week of adaptive feeding, the mice were randomly divided into 8 groups, with 8 mice in each group: control group, model group, PA53 group (intervention with PA53 bacterial solution), LH76 group (intervention with LH76 bacterial solution), PA53+LH76 group 1 (intervention with PA53 bacterial solution and LH76 bacterial solution, with a live bacteria count ratio of 1:1), PA53+LH76 group 2 (intervention with PA53 bacterial solution and LH76 bacterial solution, with a live bacteria count ratio of 5:1), PA53+LH76 group 3 (intervention with PA53 bacterial solution and LH76 bacterial solution, with a live bacteria count ratio of 1:5), and ATCC8042+ATCC15009 group (intervention with commercially available Pediococcus acidilactici ATCC8042 bacterial solution and commercially available Lactobacillus helveticus ATCC15009 bacterial solution, with a live bacteria count ratio of 1:1).
[0043] (3) Animal modeling and intervention methods:
[0044] During the entire experimental period, mice in each probiotic intervention group were fed 0.2 mL of 12% skim milk powder solution containing probiotics (dosage 1×10 9 CFU / day / mouse), the control group and model group mice were fed 0.2 mL of 12% skim milk powder solution every day. The control group mice had free access to water throughout the experiment, while the model group and each probiotic intervention group mice had free access to water for the first 7 days, and then were fed drinking water containing 3.0% dextran sulfate sodium (DSS) from the 8th day to the 14th day.
[0045] (4) Indicator analysis:
[0046] (4.1) Changes in mouse weight:
[0047] The body weight of mice was measured every day from the 1st day to the 7th day of modeling (i.e., the 8th day to the 14th day of the experiment). Figure 1 As shown in the data, the weight loss trend of mice in the model group was obvious. The intervention with various probiotics could delay and weaken the weight loss of mice to varying degrees, especially after the combined intervention with PA53 strain and LH76 strain, the effect was more significant.
[0048] (4.2) Changes in Disease Activity Index (DAI) of Mice:
[0049] The disease activity index score is an important indicator for evaluating colon damage. The DAI scoring standard is: a comprehensive score is given for the percentage of weight loss, stool viscosity and stool bleeding, and then the total score of the three results is calculated to obtain the DAI value. The percentage of weight loss (unchanged weight is 0 points, 1-5% reduction is 1 point, 5-10% reduction is 2 points, 10-15% reduction is 3 points, and reduction greater than 15% is 4 points), stool viscosity (normal is 0 points, loose stools are 2 points, and diarrhea is 4 points), and stool bleeding (normal is 0 points, occult blood positive is 2 points, and overt bleeding is 4 points).
[0050] The results are shown in Table 1. Compared with the control group, the DAI score of the mice in the model group was significantly increased. However, this trend was significantly reversed after probiotic intervention in each group, and the reversal effect was better after combined intervention of PA53 strain and LH76 strain.
[0051] Table 1
[0052]
[0053] (4.3) Mouse colon length:
[0054] After the experiment, the mice were killed and the colon length of each group of mice was recorded. Figure 2 As shown, compared with the control group, the colon length of the mice in the model group was significantly shortened. After intervention with probiotics in each group, the shortening of the colon length of the colitis mice was improved, and the effect of restoring the colon length in the PA53+LH76 group was closer to that of the control group.
[0055] (4.4) Changes in inflammatory markers in mice:
[0056] The mouse colon tissue was collected and homogenized by centrifugation, and the supernatant was collected and the levels of colon inflammatory factors were measured using a commercial kit. Figure 3-Figure 6 As shown, compared with the control group, the concentrations of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in the colon of the model group mice were significantly increased, and the concentration of interleukin-10 (IL-10) in the colon was significantly decreased. Probiotic intervention can significantly reduce the concentrations of TNF-α, IL-6, and IL-1β in the colon, and significantly increase the concentration of IL-10 in the colon. Moreover, compared with the intervention of a single probiotic, the probiotic intervention of PA53 and LH76 is more conducive to the balance of colon inflammatory factors. The above results show that the composite probiotics involved in the present invention can promote the secretion of anti-inflammatory cytokines and inhibit the secretion of proinflammatory cytokines, thereby improving colitis.
[0057] (4.5) Changes in oxidative stress-related enzymes in mice:
[0058] The mouse colon tissue was collected and homogenized by centrifugation, and the supernatant was collected to measure the activity of colon oxidative stress-related enzymes using a commercial kit. Figure 7-Figure 9 As shown in the figure, myeloperoxidase (MPO) activity and malondialdehyde (MDA) levels in the colon of mice treated with DSS increased significantly, indicating an increase in the degree of oxidative stress. However, compared with the model group, the MPO activity and MDA levels in the colon of mice significantly decreased after the intervention of probiotics, showing the significant effect of probiotics in alleviating oxidative stress. Further analysis found that the superoxide dismutase (SOD) activity in the colon tissue of the model group was significantly lower than that of the control group, indicating that the antioxidant capacity of this group of mice was inhibited when responding to oxidative stress. However, the intervention of probiotics significantly increased the SOD activity in DSS-induced colitis tissue, indicating that probiotics can enhance the body's antioxidant capacity. Moreover, compared with the intervention of a single probiotic, the combined use of PA53 and LH76, two probiotics, showed a more significant effect in regulating oxidative stress.
[0059] (4.6) Changes in short-chain fatty acids:
[0060] The cecal contents of each group of mice were collected, and the concentrations of various short-chain fatty acids (μmol / g) were determined by gas chromatography-mass spectrometry (GC-MS). The results are shown in Table 2. Compared with the control group, the concentrations of acetic acid, propionic acid, butyric acid and isobutyric acid in the model group were significantly reduced, but the probiotic intervention significantly increased the concentrations of acetic acid, propionic acid, butyric acid and isobutyric acid in the cecum of colitis mice, especially the combined intervention of PA53 strain and LH76 strain, which had the best effect.
[0061] Table 2
[0062]
[0063] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
[0064] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
[0065] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
Claims
1. A probiotic for preventing and treating colitis, characterized in that: The strain in the probiotic is Pediococcus acidilactici with a preservation number of CGMCC No.18798 Pediococcus acidilactici PA53 strain and Lactobacillus helveticus with the deposit number of CGMCC No.18796 Lactobacillus helveticus The ratio of the number of live bacteria of the PA53 strain to the number of live bacteria of the LH76 strain is 1:5-5:1; the content of live bacteria of the PA53 strain and the LH76 strain in the probiotic agent is not less than 1×10 9 CFU / g or 1×10 9 CFU / mL.
2. The probiotic according to claim 1, characterized in that The dosage form of the probiotics includes solution, lyophilized powder, capsule, tablet or granule.
3. The probiotic according to claim 2, characterized in that The dosage form of the probiotic is a solution, which is prepared by the following method: The PA53 strain and the LH76 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively and resuspended with a solvent to obtain a PA53 bacterial suspension and a LH76 bacterial suspension; the PA53 bacterial suspension and the LH76 bacterial suspension are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent.
4. The probiotic according to claim 2, characterized in that The dosage form of the probiotic is a freeze-dried powder, which is prepared by the following method: The PA53 strain and the LH76 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively, mixed with a protective agent and freeze-dried to obtain PA53 bacterial powder and LH76 bacterial powder; the PA53 bacterial powder and the LH76 bacterial powder are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent.
5. Use of the probiotic according to any one of claims 1 to 4 in the preparation of a medicament for preventing, improving or treating colitis.
6. The use according to claim 5, characterized in that: The medicine also contains auxiliary materials.
7. The use according to claim 6, characterized in that: The auxiliary materials include any one of fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, colorants, pH regulators, antioxidants, antibacterial agents or buffers, or a combination of at least two of them.
Citation Information
Patent Citations
Mixed lactobacillus for preventing and treating ulcerative colitis and application of mixed lactobacillus
CN112535693A
Application of lactobacillus paracasei in preparation of product for relieving anxiety and depression symptoms
CN114774318A
Pediococcus acidilactici ZJUIDS13 with effect of relieving ulcerative colitis and application thereof
CN116083277A
Probiotic composition and application thereof in preparation of product with anti-colitis effect
CN116179427A
Probiotic agent for improving hyperphosphatemia and application thereof
CN116515684A
